[go: up one dir, main page]

PT3725330T - Stable formulations of polypeptides and uses thereof - Google Patents

Stable formulations of polypeptides and uses thereof

Info

Publication number
PT3725330T
PT3725330T PT201760287T PT20176028T PT3725330T PT 3725330 T PT3725330 T PT 3725330T PT 201760287 T PT201760287 T PT 201760287T PT 20176028 T PT20176028 T PT 20176028T PT 3725330 T PT3725330 T PT 3725330T
Authority
PT
Portugal
Prior art keywords
polypeptides
stable formulations
formulations
stable
Prior art date
Application number
PT201760287T
Other languages
Portuguese (pt)
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of PT3725330T publication Critical patent/PT3725330T/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PT201760287T 2009-09-03 2010-09-03 Stable formulations of polypeptides and uses thereof PT3725330T (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27581609P 2009-09-03 2009-09-03
US28450209P 2009-12-18 2009-12-18

Publications (1)

Publication Number Publication Date
PT3725330T true PT3725330T (en) 2025-10-27

Family

ID=42797362

Family Applications (4)

Application Number Title Priority Date Filing Date
PT107478950T PT2473527T (en) 2009-09-03 2010-09-03 STABLE POLYETHYDE FORMULATIONS AND ITS USES
PT10747896T PT2473528E (en) 2009-09-03 2010-09-03 STABLE POLYETHYDE FORMULATIONS AND ITS USES
PT201760287T PT3725330T (en) 2009-09-03 2010-09-03 Stable formulations of polypeptides and uses thereof
PT181857723T PT3438126T (en) 2009-09-03 2010-09-03 Stable formulations of polypeptides and uses thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT107478950T PT2473527T (en) 2009-09-03 2010-09-03 STABLE POLYETHYDE FORMULATIONS AND ITS USES
PT10747896T PT2473528E (en) 2009-09-03 2010-09-03 STABLE POLYETHYDE FORMULATIONS AND ITS USES

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT181857723T PT3438126T (en) 2009-09-03 2010-09-03 Stable formulations of polypeptides and uses thereof

Country Status (12)

Country Link
US (2) US9884117B2 (en)
EP (5) EP2473528B1 (en)
CY (1) CY1121411T1 (en)
DK (3) DK2473528T3 (en)
ES (3) ES2831323T3 (en)
FI (1) FI3725330T3 (en)
HR (2) HRP20251316T1 (en)
LT (2) LT3725330T (en)
PL (3) PL3725330T3 (en)
PT (4) PT2473527T (en)
SI (1) SI2805731T1 (en)
WO (2) WO2011026948A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
MX2009012650A (en) 2007-05-24 2010-02-18 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders.
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
CN102272154A (en) 2008-10-29 2011-12-07 惠氏有限责任公司 Methods for purification of single domain antigen-binding molecules
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
MX2011010681A (en) 2009-04-10 2012-01-20 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders.
EP2417162A2 (en) 2009-04-10 2012-02-15 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
PL3725330T3 (en) * 2009-09-03 2025-12-08 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US20110059079A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
HUE044292T2 (en) 2010-02-11 2019-10-28 Ablynx Nv Methods and compositions for the preparation of aerosols
EA201892184A1 (en) 2010-03-01 2019-03-29 БАЙЕР ХЕЛЬСКЕР ЛЛСи OPTIMIZED MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
KR102023207B1 (en) * 2010-12-02 2019-11-25 온콜리틱스 바이오테크 인코포레이티드 Lyophilized viral formulations
EA201390810A1 (en) 2010-12-02 2013-09-30 Онколитикс Байотек Инк. LIQUID VIRAL COMPOSITIONS
KR102072250B1 (en) * 2011-05-27 2020-03-02 아블린쓰 엔.브이. Inhibition of bone resorption with rankl binding peptides
JP6178311B2 (en) * 2011-07-07 2017-08-09 エルエフビー ユーエスエー インコーポレイテッドＬｆｂ Ｕｓａ， Ｉｎｃ． Formulations that stabilize proteins
DK2747782T3 (en) 2011-09-23 2018-04-23 Ablynx Nv Long-term inhibition of interleukin-6-mediated signal transmission
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP3003369A4 (en) * 2013-05-28 2017-04-26 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions comprising pyrophosphate
WO2016062766A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
AU2017268394A1 (en) 2016-05-18 2019-01-03 Modernatx, Inc. Polynucleotides encoding relaxin
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
JP7186401B2 (en) * 2017-02-28 2022-12-09 フエー・イー・ベー・フエー・ゼツト・ウエー Means and methods for oral delivery of proteins
HRP20241562T1 (en) 2017-06-02 2025-01-31 Merck Patent Gmbh Adamts binding immunoglobulins
EP3934617A1 (en) * 2019-03-08 2022-01-12 Boehringer Ingelheim International GmbH Anti-il-36r antibody formulations
EP4182022A1 (en) 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
CN114681592A (en) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 Formulations comprising soluble gp130 dimers and methods of use

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2077578B (en) 1980-01-04 1984-05-16 Marchal Equip Auto End travel stop gear for motor reducer especially designed for windscreen wipers
ATE102631T1 (en) 1988-11-11 1994-03-15 Medical Res Council CLONING OF IMMUNOGLOBULIN SEQUENCES FROM THE VARIABLE DOMAINS.
DE69330523D1 (en) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru IMMUNOGLOBULINE WITHOUT LIGHT CHAINS
ES2162863T3 (en) 1993-04-29 2002-01-16 Unilever Nv PRODUCTION OF ANTIBODIES OR FRAGMENTS (FUNCTIONALIZED) OF THE SAME DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF CAMELIDAE.
FR2708622B1 (en) 1993-08-02 1997-04-18 Raymond Hamers Recombinant vector containing a sequence of a structural lipoprotein gene for the expression of nucleotide sequences.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ES2294799T3 (en) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. MOLECULES OF ANTIBODIES THAT SPECIFICALLY INTERACT WITH THE ACTIVE SITE OR HIDIDURA OF A DIANA MOLECULA.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
BR9813276A (en) 1997-10-27 2000-08-22 Unilever Nv Multivalent antigen binding protein, nucleotide sequences, expression vector, host cell, process for preparing multivalent antigen binding protein, and use thereof
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
BR9916765A (en) 1999-01-05 2001-09-25 Unilever Nv Process for producing an immunoadsorbent material, use of a protein that is linked via a covalent bond to an antibody fragment, immunosorbent material, use of a material, and, diagnostic test kit
WO2000043507A1 (en) 1999-01-19 2000-07-27 Unilever Plc Method for producing antibody fragments
AP1447A (en) 1999-04-22 2005-08-12 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins.
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
US7358096B1 (en) 1999-11-29 2008-04-15 Conopco, Inc. Immobilisation of proteins
ES2331051T3 (en) 1999-11-29 2009-12-21 Bac Ip B.V. IMMOBILIZATION OF MOLECULES OF UNION OF ANTIGENS OF A DOMAIN.
EP1134231B1 (en) 2000-03-14 2009-04-15 Unilever N.V. Antibody heavy chain variable domains against human dietary lipases, and their uses
SE0001916D0 (en) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
EP1360207B1 (en) 2000-12-13 2011-06-22 Bac Ip B.V. Protein arrays of camelid heavy-chain immunoglobulin variable domains
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
WO2003025020A1 (en) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Method of constructing camel antibody library
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy chain antibody
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
US20050037358A1 (en) 2001-12-21 2005-02-17 Serge Muyldermans Method for cloning of variable domain sequences
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
JP2006519763A (en) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． Method of administering therapeutic polypeptides and polypeptides therefor
AU2003286002B2 (en) 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
EP2390270A1 (en) 2003-01-10 2011-11-30 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
WO2005018629A1 (en) 2003-08-12 2005-03-03 Yarbrough William M Treatment for acne vulgaris and method of use
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP5113523B2 (en) 2004-10-13 2013-01-09 アブリンクス ナームローゼ フェンノートシャップ Polypeptides comprising nanoantibodies against amyloid-β and nanoantibodies TM for the treatment of neurodegenerative diseases such as Alzheimer's disease
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
AU2006205900B8 (en) * 2005-01-14 2012-04-05 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets
WO2006079372A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP2949668B1 (en) 2005-05-18 2019-08-14 Ablynx N.V. Improved nanobodies tm against tumor necrosis factor-alpha
BRPI0609797B8 (en) 2005-05-20 2021-05-25 Ablynx Nv improved nanobodies for the treatment of aggregation-mediated disorders
DE102005023617A1 (en) 2005-05-21 2006-11-23 Aspre Ag Method for mixing colors in a display
PT1899378E (en) * 2005-06-21 2010-01-26 Xoma Technology Ltd Il-1 beta binding antibodies and fragments thereof
CN101321784A (en) * 2005-10-11 2008-12-10 埃博灵克斯股份有限公司 Nanobodies TM and peptides against EGFR and IGF-IR
AU2006344395B2 (en) * 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
CN101378782A (en) 2005-12-21 2009-03-04 惠氏公司 Protein formulations with reduced viscosity and uses thereof
SE530085C2 (en) 2006-01-30 2008-02-26 Timothy Richard Vinnicombe Microwave Oven
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
JP2009529339A (en) * 2006-03-13 2009-08-20 アブリンクス エン．ヴェー． Amino acid sequences targeting IL-6 and polypeptides comprising the same and treating diseases and disorders associated with IL-6 mediated signaling
KR100817251B1 (en) 2006-06-28 2008-03-27 주식회사 삼정산업 Steel pallet
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
CA2663892A1 (en) 2006-09-25 2008-04-03 Medimmune, Llc Stabilized antibody formulations and uses thereof
EP2081960B1 (en) * 2006-10-27 2018-06-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
CN101631535A (en) 2006-12-06 2010-01-20 惠氏公司 High protein concentration formulations containing mannitol
AU2007331596A1 (en) 2006-12-13 2008-06-19 Ablynx N.V. Polypeptides specific for complexes involved in receptor-mediated signaling, such as the IL-6/IL-6 receptor complex
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
US20100166734A1 (en) 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
US7695718B2 (en) * 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
EP2101801A1 (en) 2006-12-20 2009-09-23 Ablynx N.V. Oral delivery of polypeptides
JP5577098B2 (en) 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド Stable buffered formulations containing polypeptides
WO2008077945A2 (en) 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
US20110118185A9 (en) 2007-02-21 2011-05-19 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
EP2160409A1 (en) 2007-05-24 2010-03-10 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
MX2009012650A (en) 2007-05-24 2010-02-18 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders.
AU2008328779B2 (en) 2007-11-27 2014-06-05 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
KR20100120289A (en) 2008-01-15 2010-11-15 애보트 게엠베하 운트 콤파니 카게 Powdered protein compositions and methods of making same
CA2712432C (en) * 2008-01-29 2018-09-25 Ablynx N.V. Methods to stabilize single variable domains
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
CN102202643A (en) 2008-02-07 2011-09-28 安姆根有限公司 Stabilized protein compositions
WO2009109635A2 (en) * 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
WO2009115614A2 (en) 2008-03-21 2009-09-24 Ablynx Nv Von willebrand factor specific binders and methods of use therefor
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
CN102224169A (en) * 2008-11-26 2011-10-19 葛兰素集团有限公司 Polypeptides, antibody variable domains and antagonists
AU2010205627B2 (en) * 2009-01-14 2015-04-02 Ablynx Nv Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP2391384A4 (en) * 2009-01-29 2012-12-26 Medimmune Llc Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
WO2010100135A1 (en) * 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
PL3725330T3 (en) * 2009-09-03 2025-12-08 Ablynx N.V. Stable formulations of polypeptides and uses thereof

Also Published As

Publication number Publication date
PL3725330T3 (en) 2025-12-08
DK3725330T3 (en) 2025-10-27
WO2011026945A1 (en) 2011-03-10
WO2011026948A1 (en) 2011-03-10
DK2473527T3 (en) 2017-03-06
SI2805731T1 (en) 2019-02-28
CY1121411T1 (en) 2020-05-29
ES2831323T3 (en) 2021-06-08
US20120201812A1 (en) 2012-08-09
EP2805731A2 (en) 2014-11-26
LT2805731T (en) 2019-02-11
EP3725330B1 (en) 2025-08-06
EP2805731A3 (en) 2015-04-01
PT3438126T (en) 2020-11-09
EP2473528A1 (en) 2012-07-11
ES2531083T3 (en) 2015-03-10
PL2473528T3 (en) 2015-05-29
US20120244158A1 (en) 2012-09-27
ES2617180T3 (en) 2017-06-15
EP3725330A1 (en) 2020-10-21
DK2473528T3 (en) 2015-03-02
PL3438126T3 (en) 2021-03-08
US9884117B2 (en) 2018-02-06
HK1204284A1 (en) 2015-11-13
EP2473527B1 (en) 2016-11-30
EP2805731B1 (en) 2018-10-31
LT3725330T (en) 2025-11-25
FI3725330T3 (en) 2025-11-14
EP2473528B1 (en) 2014-12-03
EP2473527A1 (en) 2012-07-11
PT2473527T (en) 2017-02-27
HRP20251316T1 (en) 2025-12-05
HRP20190137T1 (en) 2019-03-22
PT2473528E (en) 2015-03-04
EP3438126A1 (en) 2019-02-06
EP3438126B1 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
PL2473528T3 (en) Stable formulations of polypeptides and uses thereof
SG10201605794PA (en) Stable Pharmaceutical Composition And Methods Of Using Same
IL217280A0 (en) Compositions comprising combinations of phyto-cannabinoids and uses thereof
ZA201300193B (en) Formulations of rifaximin and uses thereof
GB0916576D0 (en) Polypeptides and uses thereof
GB0916578D0 (en) Polypeptides and uses thereof
IL209385A0 (en) Formulations of 5-fluorocytosine and uses thereof
SI2605757T1 (en) Nalbuphine-based formulations and uses thereof
IL219155A0 (en) Pharmaceutical formulations of nitrite and uses thereof
IL219470A0 (en) Compositions containing fractalknie-binding proteins and uses thereof
IL247929B (en) Stable sns-595 compositions and methods of preparation
IL217135A0 (en) Stabilized herbicidal formulations and methods of use
IL224191A (en) Formulations of 14 -epi-analogues of vitamin d and cmc
GB0905790D0 (en) Novel polypeptides and use thereof
IL219018A (en) Pharmaceutical compositions of radezolid and uses thereof
ZA201200260B (en) Polyphenylsulphone-polytetrafluroethylene compositions and use thereof
EP2508598A4 (en) Lipase powder preparation and use thereof